Imukin

Recombinant human interferon gamma-1b, the active ingredient in Imukin, is a cytokine immunomodulator presented as a sterile solution for subcutaneous use. It is indicated for specific rare immunodeficiency and bone disorders and is administered under medical supervision. GNH USA supplies Imukin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imukin is used to target disorders that involve defective immune activation or abnormal bone remodeling. - Chronic granulomatous disease: improves microbial killing by enhancing macrophage function. - Severe malignant osteopetrosis: stimulates osteoclast activity to reduce bone density and alleviate disease complications.

Imukin may cause a range of adverse reactions that vary in frequency and severity. Common Side Effects: - Flu‑like symptoms: fever, chills, myalgia. - Injection site reactions: redness, swelling, pain. - Fatigue or malaise. - Headache. - Nausea. Serious or Rare Side Effects: - Hematologic abnormalities: anemia, leukopenia, thrombocytopenia. - Hepatic enzyme elevations. - Autoimmune phenomena such as lupus‑like syndrome. - Severe allergic reactions including anaphylaxis. - Pulmonary complications: interstitial pneumonitis.

Before initiating Imukin, clinicians should assess baseline laboratory values and monitor patients regularly. - Baseline labs: obtain complete blood count and liver function tests. - Monitor infection risk: watch for opportunistic infections during therapy. - Autoimmunity: be alert for signs of autoimmune disease emergence. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imukin can interact with other agents that affect immune function or hematologic parameters. Major Interactions (Avoid): - Immunosuppressants (e.g., high‑dose corticosteroids, calcineurin inhibitors): may blunt therapeutic effect. - Live vaccines: increased risk of vaccine‑derived infection. Moderate Interactions (Monitor Closely): - Antiviral agents (e.g., ribavirin): may enhance hematologic toxicity. - Chemotherapeutic drugs: potential additive bone marrow suppression. - Anticoagulants: monitor for altered coagulation parameters.